文献速递预防保健、筛查与疫苗常见症状与未分化疾病

成人社区获得性肺炎:快速证据回顾

Community-Acquired Pneumonia in Adults: Rapid Evidence Review.
PubMed 文献 · Am Fam Physician · 2022-01-01

本文综述成人社区获得性肺炎(CAP)的流行病学、诊断与治疗。65岁以上人群住院率约2%,住院患者30天死亡率6%。诊断依靠病史、体检和影像;不推荐降钙素原。CRB-65可用于基层风险分层。治疗按有无合并症选择抗生素,并给出肺炎球菌疫苗接种建议。

要点

  • 65岁以上人群CAP住院率约2%,住院患者30天死亡率6%。
  • 诊断结合病史、体检和胸片、肺超声或CT;不推荐降钙素原。
  • CRB-65是基层验证良好的风险分层工具,无需实验室检查。

核心结论

  • CAP诊断通常结合病史、体格检查及胸部影像学检查,不推荐检测降钙素原。
  • CRB-65是基层适用的风险分层工具,无需实验室检查。
  • 抗生素选择依据有无合并症及病情严重程度,并应针对性覆盖MRSA或铜绿假单胞菌的高危患者。
  • 65岁以上成人及19至64岁有基础疾病者应接种肺炎球菌疫苗,所有成人应接种流感和SARS-CoV-2疫苗。

研究设计与样本

  • 本文为快速证据回顾,总结成人CAP的诊断、风险分层、治疗及预防证据。
  • 文中引用的病原学数据来自COVID-19大流行前的研究。

主要发现

  • 65岁及以上人群CAP住院率约2%,住院患者30天死亡率6%。
  • 大流行前研究中,11%患者检出细菌病原体,23%检出病毒病原体,62%未检出病原体。
  • 某些症状和体征有助于诊断CAP和选择影像学检查。

关键数值与推荐

  • 无合并症门诊患者推荐阿莫西林、多西环素或大环内酯类,大环内酯类仅用于肺炎链球菌对大环内酯类耐药率低于25%的地区。
  • 有合并症门诊患者及非重症住院患者推荐β-内酰胺类或三代头孢菌素联合大环内酯类,或呼吸喹诺酮类单药治疗。
  • 仅当患者存在MRSA或铜绿假单胞菌感染危险因素时才应针对这些病原体治疗。
  • 65岁及以上成人或19至64岁有基础疾病者应接种20价肺炎球菌结合疫苗,或15价肺炎球菌结合疫苗后一年接种23价肺炎球菌多糖疫苗。
  • 不再推荐13价肺炎球菌结合疫苗用于常规接种;CDC推荐所有成人接种流感和SARS-CoV-2疫苗。

临床怎么用

  • 基层医生可结合病史、体检和影像学诊断CAP,不检测降钙素原。
  • 使用CRB-65进行风险分层,无需实验室检查。
  • 按有无合并症和病情严重程度选择抗生素方案。
  • 仅对有MRSA或铜绿假单胞菌危险因素的患者覆盖这些病原体。
  • 按推荐为成人接种肺炎球菌、流感和SARS-CoV-2疫苗。

局限性

  • 病原学数据来自COVID-19大流行前的研究,可能不反映当前病原谱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Community-acquired pneumonia (CAP) is a common condition with a hospitalization rate of about 2% in people 65 years or older and is associated with a 30-day mortality rate of 6% in hospitalized patients. In studies conducted before the COVID-19 pandemic, a bacterial pathogen was identified in 11% of patients, a viral pathogen in 23% of patients, and no organism in 62% of patients. Certain signs and symptoms can be helpful in diagnosing CAP and selecting imaging studies. Diagnosis is usually made with a combination of history, physical examination, and findings on chest radiography, lung ultrasonography, or computed tomography. Procalcitonin measurement is not recommended. CRB-65 (confusion, respiratory rate, blood pressure, 65 years of age) is a well-validated risk stratification tool in the primary care setting and does not require laboratory testing. For outpatients without comorbidities, treatment with amoxicillin, doxycycline, or a macrolide is recommended (the latter only in areas where pneumococcal resistance to macrolides is less than 25%). In outpatients with comorbidities and inpatients with nonsevere pneumonia, a combination of a beta-lactam or third-generation cephalosporin plus a macrolide, or monotherapy with a respiratory fluoroquinolone is recommended. Patients should be treated for methicillin-resistant Staphylococcus aureus or Pseudomonas infection only if they present with risk factors for those pathogens. All adults 65 years or older or those 19 to 64 with underlying conditions should receive the 20-valent pneumococcal conjugate vaccine alone or the 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine one year later. The 13-valent pneumococcal conjugate vaccine is no longer recommended for routine administration. The Centers for Disease Control and Prevention recommends vaccination against influenza and SARS-CoV-2 viruses for all adults.

来源:Am Fam Physician,查看原文。版权归原作者所有。

引用

  1. Womack J, Kropa J. Community-Acquired Pneumonia in Adults: Rapid Evidence Review. Am Fam Physician. 2022. PMID: 35704808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。